Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15775201 | 0.86 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HTR1DDRD4 | |
| SCHEMBL32677895 | 0.74 | DRD2 (0.42) | HSD11B1DRD2DRD3HTR1DSTS | |
| SCHEMBL15775185 | 0.74 | DRD2 (0.42) | HSD11B1DRD2DRD3HTR1DSTS | |
| SCHEMBL32677899 | 0.74 | DRD2 (0.42) | HSD11B1DRD2DRD3HTR1DSTS | |
| SCHEMBL21178299 | 0.73 | PPARG (0.38) | HSD11B1DRD2DRD3HTR1DSTS | |
| SCHEMBL16499628 | 0.73 | PPARG (0.38) | HSD11B1DRD2DRD3HTR1DSTS | |
| SCHEMBL17393794 | 0.72 | HSD11B1 (0.41) | HSD11B1DRD2DRD3HTR1DCXCR2 | |
| SCHEMBL9619914 | 0.68 | HSD11B1 (0.39) | HSD11B1DRD2DRD3HTR1DCXCR2 | |
| SCHEMBL26817513 | 0.68 | HTR1D (0.38) | HSD11B1DRD2DRD3HTR1DCXCR2 | |
| SCHEMBL1774731 | 0.68 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HTR1DDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | HSD11B1 4520/4885DRD2 1611/4885DRD3 2094/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | HSD11B1 4520/4885DRD2 1611/4885DRD3 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.